Advancements in Antibacterial Therapy: Feature Papers.

Giancarlo Angeles Flores, Gaia Cusumano, Roberto Venanzoni, Paola Angelini
Author Information
  1. Giancarlo Angeles Flores: Department of Chemistry, Biology and Biotechnology, University of Perugia, Via del Giochetto, 06122 Perugia, Italy.
  2. Gaia Cusumano: Department of Chemistry, Biology and Biotechnology, University of Perugia, Via del Giochetto, 06122 Perugia, Italy. ORCID
  3. Roberto Venanzoni: Department of Chemistry, Biology and Biotechnology, University of Perugia, Via del Giochetto, 06122 Perugia, Italy. ORCID
  4. Paola Angelini: Department of Chemistry, Biology and Biotechnology, University of Perugia, Via del Giochetto, 06122 Perugia, Italy. ORCID

Abstract

Antimicrobial resistance (AMR) is a growing global health crisis that threatens the efficacy of antibiotics and modern medical interventions. The emergence of multidrug-resistant (MDR) pathogens, exacerbated by the misuse of antibiotics in healthcare and agriculture, underscores the urgent need for innovative solutions. (1) Background: AMR arises from complex interactions between human, animal, and environmental health, further aggravated by the overuse and inadequate regulation of antibiotics. Conventional treatments are increasingly ineffective, necessitating alternative strategies. Emerging approaches, including bacteriophage therapy, antimicrobial peptides (AMPs), nanotechnology, microbial extracellular vesicles (EVs), and CRISPR-based antimicrobials, provide novel mechanisms that complement traditional antibiotics in combating resistant pathogens. (2) Methods: This review critically analyzes advanced antibacterial strategies in conjunction with systemic reforms such as antimicrobial stewardship programs, the One Health framework, and advanced surveillance tools. These methods can enhance resistance detection, guide interventions, and promote sustainable practices. Additionally, economic, logistical, and regulatory challenges impeding their implementation are evaluated. (3) Results: Emerging technologies, such as CRISPR and nanotechnology, exhibit promising potential in targeting resistance mechanisms. However, disparities in resource distribution and regulatory barriers hinder widespread adoption. Public-private partnerships and sustainable agriculture practices are critical to overcoming these obstacles. (4) Conclusions: A holistic and integrated approach is essential for mitigating the impact of AMR. By aligning innovative therapeutic strategies with global health policies, fostering interdisciplinary collaboration, and ensuring equitable resource distribution, we can develop a sustainable response to this 21st-century challenge.

Keywords

References

  1. Antibiotics (Basel). 2024 Jan 25;13(2): [PMID: 38391507]
  2. EFSA J. 2021 Jun 17;19(6):e06651 [PMID: 34178158]
  3. Int J Nanomedicine. 2024 Aug 21;19:8573-8601 [PMID: 39185348]
  4. Pharmaceuticals (Basel). 2024 Aug 29;17(9): [PMID: 39338299]
  5. Lancet Reg Health Eur. 2023 Jul 26;33:100705 [PMID: 37546576]
  6. J Clin Lab Anal. 2022 Sep;36(9):e24655 [PMID: 35949048]
  7. Microorganisms. 2022 Feb 14;10(2): [PMID: 35208891]
  8. Antibiotics (Basel). 2024 Aug 23;13(9): [PMID: 39334969]
  9. Molecules. 2018 Mar 30;23(4): [PMID: 29601469]
  10. BMC Public Health. 2023 Jun 3;23(1):1059 [PMID: 37268899]
  11. RSC Adv. 2024 Oct 22;14(45):33568-33586 [PMID: 39439838]
  12. Antibiotics (Basel). 2022 May 25;11(6): [PMID: 35740115]
  13. Nat Commun. 2013;4:1477 [PMID: 23403578]
  14. J Intensive Care. 2020 Jan 28;8:13 [PMID: 32015881]
  15. Poult Sci. 2024 Feb;103(2):103278 [PMID: 38052127]
  16. Ann Clin Microbiol Antimicrob. 2024 Nov 24;23(1):103 [PMID: 39581990]
  17. Front Med (Lausanne). 2022 Oct 13;9:940454 [PMID: 36313997]
  18. Heliyon. 2024 Sep 20;10(19):e38079 [PMID: 39386776]
  19. BMJ. 2021 Mar 29;372:n71 [PMID: 33782057]
  20. Healthcare (Basel). 2023 Jul 05;11(13): [PMID: 37444780]
  21. Infect Drug Resist. 2021 Feb 05;14:415-434 [PMID: 33574682]
  22. Med Sci (Basel). 2021 Feb 21;9(1): [PMID: 33669981]
  23. Prog Mol Biol Transl Sci. 2024;208:59-81 [PMID: 39266188]
  24. Brief Bioinform. 2024 Jan 22;25(2): [PMID: 38446739]
  25. Microorganisms. 2023 Apr 17;11(4): [PMID: 37110473]
  26. Heliyon. 2024 Jul 16;10(14):e34692 [PMID: 39149034]
  27. Mol Ther. 2024 Sep 4;32(9):2939-2949 [PMID: 38414242]
  28. J Antibiot (Tokyo). 2017 Dec;70(12):1087-1096 [PMID: 29089600]
  29. Front Microbiol. 2020 Jul 02;11:1132 [PMID: 32714283]
  30. Antibiotics (Basel). 2019 Nov 13;8(4): [PMID: 31766123]
  31. Nat Microbiol. 2024 Jun;9(6):1434-1453 [PMID: 38834776]
  32. Microb Pathog. 2024 Dec;197:107088 [PMID: 39477033]
  33. Clin Transl Sci. 2021 Jan;14(1):86-93 [PMID: 32961010]
  34. J Clin Transl Res. 2015 Dec 1;1(3):140-167 [PMID: 30873451]
  35. Signal Transduct Target Ther. 2024 Feb 5;9(1):27 [PMID: 38311623]
  36. Front Bioeng Biotechnol. 2024 Sep 27;12:1476737 [PMID: 39398642]
  37. Plants (Basel). 2023 Aug 28;12(17): [PMID: 37687324]
  38. Antibiotics (Basel). 2024 Nov 12;13(11): [PMID: 39596769]
  39. Cell Host Microbe. 2024 Jun 12;32(6):786-793 [PMID: 38870896]
  40. Cancer Commun (Lond). 2024 Feb;44(2):205-225 [PMID: 38155418]
  41. Antibiotics (Basel). 2022 Feb 04;11(2): [PMID: 35203804]
  42. Front Cell Infect Microbiol. 2024 Jan 19;14:1352273 [PMID: 38322672]
  43. Biosensors (Basel). 2022 Sep 04;12(9): [PMID: 36140107]
  44. Eur J Clin Microbiol Infect Dis. 2023 Aug;42(8):919-928 [PMID: 37407800]
  45. Front Pharmacol. 2024 Aug 16;15:1444781 [PMID: 39221153]
  46. Antibiotics (Basel). 2024 Dec 08;13(12): [PMID: 39766587]
  47. PLoS Pathog. 2024 May 2;20(5):e1012143 [PMID: 38696356]
  48. Curr Opin Microbiol. 2019 Oct;51:72-80 [PMID: 31733401]
  49. PLoS Pathog. 2021 May 13;17(5):e1009508 [PMID: 33984071]
  50. Adv Drug Deliv Rev. 2021 Jun;173:125-140 [PMID: 33774113]
  51. BMC Microbiol. 2022 Aug 20;22(1):203 [PMID: 35987607]
  52. Eng Microbiol. 2023 Jun 20;3(4):100101 [PMID: 39628916]
  53. Microorganisms. 2024 Sep 21;12(9): [PMID: 39338594]
  54. Evolution. 2019 May;73(5):1001-1011 [PMID: 30953575]
  55. Antibiotics (Basel). 2023 Mar 04;12(3): [PMID: 36978383]
  56. Antibiotics (Basel). 2022 Jun 12;11(6): [PMID: 35740200]
  57. Vaccines (Basel). 2024 Jun 26;12(7): [PMID: 39066349]
  58. Front Genome Ed. 2023 Jun 21;5:1200987 [PMID: 37415849]
  59. Pathogens. 2024 Nov 28;13(12): [PMID: 39770308]
  60. Front Microbiol. 2024 Oct 03;15:1455759 [PMID: 39421555]
  61. Microbiol Spectr. 2023 Mar 22;:e0517922 [PMID: 36946779]
  62. Global Health. 2024 Oct 17;20(1):73 [PMID: 39415207]
  63. Infect Drug Resist. 2023 Dec 08;16:7515-7545 [PMID: 38089962]
  64. Front Cell Infect Microbiol. 2024 Oct 07;14:1428637 [PMID: 39435185]
  65. Lancet Microbe. 2025 Jan;6(1):100947 [PMID: 39305919]
  66. J Anim Sci Technol. 2024 Mar;66(2):266-278 [PMID: 38628683]
  67. RSC Med Chem. 2023 Jul 21;14(9):1591-1602 [PMID: 37731693]
  68. Microorganisms. 2023 Jun 19;11(6): [PMID: 37375116]
  69. Front Microbiol. 2024 Jul 31;15:1390765 [PMID: 39144233]
  70. Foods. 2022 May 16;11(10): [PMID: 35627000]
  71. Pharmacol Res. 2024 Sep;207:107321 [PMID: 39038631]
  72. Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0028121 [PMID: 34097492]
  73. Infect Drug Resist. 2024 Nov 26;17:5229-5245 [PMID: 39619730]
  74. Antibiotics (Basel). 2023 Nov 03;12(11): [PMID: 37998792]
  75. J Immunol Res. 2022 Feb 17;2022:8092170 [PMID: 35224113]
  76. Antibiotics (Basel). 2023 Mar 01;12(3): [PMID: 36978354]
  77. Biomed Pharmacother. 2024 Jan;170:116083 [PMID: 38163395]
  78. Antibiotics (Basel). 2024 Aug 21;13(8): [PMID: 39200083]
  79. Front Microbiol. 2022 Feb 18;13:817844 [PMID: 35250933]
  80. Pharmaceutics. 2021 Aug 25;13(9): [PMID: 34575408]
  81. J Anaesthesiol Clin Pharmacol. 2017 Jul-Sep;33(3):300-305 [PMID: 29109626]
  82. Biomedicines. 2023 Jan 31;11(2): [PMID: 36830949]
  83. Int J Mol Sci. 2024 Oct 08;25(19): [PMID: 39409116]
  84. Lancet Glob Health. 2018 Nov;6(11):e1196-e1252 [PMID: 30196093]
  85. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020 Jul;12(4):e1623 [PMID: 32147974]
  86. Antibiotics (Basel). 2024 Sep 25;13(10): [PMID: 39452186]
  87. Infect Drug Resist. 2019 Apr 24;12:965-975 [PMID: 31190901]
  88. Antibiotics (Basel). 2022 Sep 08;11(9): [PMID: 36139995]
  89. Vet Res. 2001 May-Aug;32(3-4):261-73 [PMID: 11432417]
  90. Cell. 2023 Jan 5;186(1):17-31 [PMID: 36608652]
  91. Molecules. 2024 Dec 31;30(1): [PMID: 39795190]
  92. Nanomaterials (Basel). 2025 Jan 24;15(3): [PMID: 39940158]
  93. ACS Infect Dis. 2023 Nov 10;9(11):2062-2071 [PMID: 37819866]
  94. Signal Transduct Target Ther. 2024 Feb 21;9(1):34 [PMID: 38378653]
  95. Molecules. 2018 Jan 30;23(2): [PMID: 29385736]
  96. Antibiotics (Basel). 2020 May 28;9(6): [PMID: 32481671]
  97. J Funct Biomater. 2024 Jul 15;15(7): [PMID: 39057315]
  98. Infect Drug Resist. 2020 Dec 29;13:4713-4738 [PMID: 33402841]
  99. Pharmaceuticals (Basel). 2023 Nov 22;16(12): [PMID: 38139765]
  100. Antibiotics (Basel). 2024 Sep 11;13(9): [PMID: 39335043]
  101. Microbiology (Reading). 2023 May;169(5): [PMID: 37224055]
  102. Nucleic Acids Res. 2024 Jun 10;52(10):6079-6091 [PMID: 38661215]
  103. Nat Rev Microbiol. 2024 Oct;22(10):598-616 [PMID: 38831030]
  104. Drug Discov Ther. 2024 Nov 15;18(5):269-276 [PMID: 39462601]
  105. Adv Biomed Res. 2024 Nov 30;13:113 [PMID: 39717242]
  106. Vet Sci. 2024 Aug 27;11(9): [PMID: 39330773]
  107. Expert Opin Ther Pat. 2020 Dec;30(12):897-900 [PMID: 32985275]
  108. ACS Infect Dis. 2024 Apr 12;10(4):1034-1055 [PMID: 38428037]
  109. J Antimicrob Chemother. 2021 Oct 11;76(11):2748-2756 [PMID: 34180526]
  110. Life (Basel). 2025 Jan 02;15(1): [PMID: 39859989]
  111. ACS Omega. 2022 Dec 10;7(50):45962-45980 [PMID: 36570317]
  112. Drug Resist Updat. 2024 Nov;77:101147 [PMID: 39236354]
  113. Mol Biol Rep. 2023 Oct;50(10):8639-8651 [PMID: 37535245]
  114. Pharmaceuticals (Basel). 2023 Nov 15;16(11): [PMID: 38004480]
  115. Sci Total Environ. 2024 Nov 25;953:175971 [PMID: 39236811]
  116. Antibiotics (Basel). 2024 Jan 26;13(2): [PMID: 38391511]
  117. Curr Med Res Opin. 2015 Apr;31(4):707-21 [PMID: 25697677]
  118. Curr Res Microb Sci. 2021 Apr 02;2:100030 [PMID: 34841321]
  119. J Nanobiotechnology. 2023 Jul 20;21(1):231 [PMID: 37475025]
  120. Lasers Med Sci. 2024 May 29;39(1):144 [PMID: 38809462]

Word Cloud

Created with Highcharts 10.0.0antibioticsresistanceAMRhealthstrategiesantimicrobialnanotechnologysustainableglobalinterventionsMDRpathogensagricultureinnovativeEmergingbacteriophagepeptidesAMPsextracellularvesiclesEVsCRISPR-basedantimicrobialsmechanismsadvancedcanpracticesregulatoryresourcedistributionAntimicrobialgrowingcrisisthreatensefficacymodernmedicalemergencemultidrug-resistantexacerbatedmisusehealthcareunderscoresurgentneedsolutions1Background:arisescomplexinteractionshumananimalenvironmentalaggravatedoveruseinadequateregulationConventionaltreatmentsincreasinglyineffectivenecessitatingalternativeapproachesincludingtherapymicrobialprovidenovelcomplementtraditionalcombatingresistant2Methods:reviewcriticallyanalyzesantibacterialconjunctionsystemicreformsstewardshipprogramsOneHealthframeworksurveillancetoolsmethodsenhancedetectionguidepromoteAdditionallyeconomiclogisticalchallengesimpedingimplementationevaluated3Results:technologiesCRISPRexhibitpromisingpotentialtargetingHoweverdisparitiesbarriershinderwidespreadadoptionPublic-privatepartnershipscriticalovercomingobstacles4Conclusions:holisticintegratedapproachessentialmitigatingimpactaligningtherapeuticpoliciesfosteringinterdisciplinarycollaborationensuringequitabledevelopresponse21st-centurychallengeAdvancementsAntibacterialTherapy:FeaturePapersbacteriabiofilmbroad-spectrumvaccines

Similar Articles

Cited By